Abstract
The eye is a very complex organ consisting of many anterior and posterior tissues. Studies over the last 2 decades have demonstrated the promise of using nucleic acids, such as DNA, siRNA, antisense oligonucleotide (AS-ODNs), and aptamer, in treating acquired as well as inherited ocular diseases. Among various ocular drug delivery strategies, topical administration is the most convenient route. However, the presence of several anatomical and physiological barriers restricts this administration only for anterior tissues. Stability, physicochemical properties, and propensity of spreading to adjacent tissues are limiting factors for site-specific delivery of nucleic acids in posterior tissues. To overcome these hurdles, several novel routes and delivery systems have been developed in recent years. These novel delivery systems possess several advantages including sustained and site-specific delivery of therapeutic nucleic acids. In this chapter, attempts have been made to introduce the structure of the eye, the major types of nucleic acids for the treatment of ocular diseases, and various strategies that have been used to achieve site-specific delivery of nucleic acids to the eye.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Fattal E, Bochot A (2006) Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA. Adv Drug Deliv Rev 58(11):1203–1223
Ali RR (2012) Ocular gene therapy: introduction to the special issue. Gene Ther 19(2):119–120
Klausner EA et al (2007) Corneal gene therapy. J Control Release 124(3):107–133
Bejjani RA et al (2007) Electrically assisted ocular gene therapy. Surv Ophthalmol 52(2):196–208
Kuno N, Fujii S (2011) Recent advances in ocular drug delivery systems. Polymers 3(1):193–221
Hosoya K, Lee VH, Kim KJ (2005) Roles of the conjunctiva in ocular drug delivery: a review of conjunctival transport mechanisms and their regulation. Eur J Pharm Biopharm 60(2):227–240
Doolittle RF (1988) Lens proteins. More molecular opportunism. Nature 336(6194):18
Gaudana R et al (2010) Ocular drug delivery. AAPS J 12(3):348–360
(2006) Human Eye Physiology. Available from: http://cmp.felk.cvut.cz/~hlavac/TeachPresEn/15ImageAnalysis/61HumanEyePhysiology.ppt
Levin LA, Nilsson SFE, Hoeve JV, Wu S, Kaufman PL, Alm A (2012) Adler’s physiology of the eye. 11th edn. US Elsevier Health Bookshop. Available from: http://www.us.elsevierhealth.com/Medicine/Ophthalmology/book/9780323057141/Adlers-Physiology-of-the-Eye/
Myles ME, Neumann DM, Hill JM (2005) Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis. Adv Drug Deliv Rev 57(14):2063–2079
Cheruvu NP, Kompella UB (2006) Bovine and porcine transscleral solute transport: influence of lipophilicity and the Choroid-Bruch’s layer. Invest Ophthalmol Vis Sci 47(10):4513–4522
Kim SH et al (2007) Transport barriers in transscleral drug delivery for retinal diseases. Ophthalmic Res 39(5):244–254
Robinson MR et al (2006) A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide. Exp Eye Res 82(3):479–487
Hildebrand G, Fielder A (2011) Anatomy and physiology of the retina. In: Reynolds J, Olitsky S (eds) Pediatric retina. Springer, Berlin, pp 39–65
Provis JM (2001) Development of the primate retinal vasculature. Prog Retin Eye Res 20(6):799–821
Trotter RR (1968) Cornea and sclera. Arch Ophthalmol 79(3):338–348
Colella P, Cotugno G, Auricchio A (2009) Ocular gene therapy: current progress and future prospects. Trends Mol Med 15(1):23–31
Crooke ST (2004) Antisense strategies. Curr Mol Med 4(5):465–487
Burmeister PE et al (2005) Direct in vitro selection of a 2'-O-methyl aptamer to VEGF. Chem Biol 12(1):25–33
Klebe S et al (2001) Gene transfer to ovine corneal endothelium. Clin Experiment Ophthalmol 29(5):316–322
Arancibia-Carcamo CV et al (1998) Lipoadenofection-mediated gene delivery to the corneal endothelium: prospects for modulating graft rejection. Transplantation 65(1):62–67
Andrieu-Soler C et al (2006) Ocular gene therapy: a review of nonviral strategies. Mol Vis 12:1334–1347
Liaw J, Chang SF, Hsiao FC (2001) In vivo gene delivery into ocular tissues by eye drops of poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) (PEO-PPO-PEO) polymeric micelles. Gene Ther 8(13):999–1004
Hao J et al (2010) Gene delivery to cornea. Brain Res Bull 81(2–3):256–261
Tong YC et al (2007) Eye drop delivery of nano-polymeric micelle formulated genes with cornea-specific promoters. J Gene Med 9(11):956–966
Wen SF et al (2003) Characterization of adenovirus p21 gene transfer, biodistribution, and immune response after local ocular delivery in New Zealand white rabbits. Exp Eye Res 77(3):355–365
Kim B et al (2004) Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal keratitis. Am J Pathol 165(6):2177–2185
Carlson EC et al (2004) In vivo gene delivery and visualization of corneal stromal cells using an adenoviral vector and keratocyte-specific promoter. Invest Ophthalmol Vis Sci 45(7):2194–2200
Jun AS, Larkin DF (2003) Prospects for gene therapy in corneal disease. Eye (Lond) 17(8):906–911
Spencer B et al (2000) Herpes simplex virus-mediated gene delivery to the rodent visual system. Invest Ophthalmol Vis Sci 41(6):1392–1401
Bainbridge JW et al (2001) In vivo gene transfer to the mouse eye using an HIV-based lentiviral vector; efficient long-term transduction of corneal endothelium and retinal pigment epithelium. Gene Ther 8(21):1665–1668
George AJ et al (2000) Gene delivery to the corneal endothelium. Am J Respir Crit Care Med 162(4 Pt 2):S194–S200
Borras T (2003) Recent developments in ocular gene therapy. Exp Eye Res 76(6):643–652
Tanelian DL et al (1997) Controlled gene gun delivery and expression of DNA within the cornea. Biotechniques 23(3):484–488
Mohan RR et al (2012) Gene therapy in the cornea: 2005–present. Prog Retin Eye Res 31(1):43–64
Bauer D et al (2006) Immunomodulation by topical particle-mediated administration of cytokine plasmid DNA suppresses herpetic stromal keratitis without impairment of antiviral defense. Graefes Arch Clin Exp Ophthalmol 244(2):216–225
Oshima Y et al (1998) Targeted gene transfer to corneal endothelium in vivo by electric pulse. Gene Ther 5(10):1347–1354
Sakamoto T et al (1999) Target gene transfer of tissue plasminogen activator to cornea by electric pulse inhibits intracameral fibrin formation and corneal cloudiness. Hum Gene Ther 10(15):2551–2557
Oshima Y et al (2002) Targeted gene transfer to corneal stroma in vivo by electric pulses. Exp Eye Res 74(2):191–198
Eljarrat-Binstock E, Domb AJ (2006) Iontophoresis: a non-invasive ocular drug delivery. J Control Release 110(3):479–489
Halhal M et al (2004) Iontophoresis: from the lab to the bed side. Exp Eye Res 78(3):751–757
Bochot A et al (1998) Comparison of the ocular distribution of a model oligonucleotide after topical instillation in rabbits of conventional and new dosage forms. J Drug Target 6(4):309–313
Berdugo M et al (2003) Delivery of antisense oligonucleotide to the cornea by iontophoresis. Antisense Nucleic Acid Drug Dev 13(2):107–114
Eljarrat-Binstock E et al (2008) Charged nanoparticles delivery to the eye using hydrogel iontophoresis. J Control Release 126(2):156–161
Yasukawa T et al (2004) Drug delivery systems for vitreoretinal diseases. Prog Retin Eye Res 23(3):253–281
Anand V et al (2000) Additional transduction events after subretinal readministration of recombinant adeno-associated virus. Hum Gene Ther 11(3):449–457
Acland GM et al (2001) Gene therapy restores vision in a canine model of childhood blindness. Nat Genet 28(1):92–95
Acland GM et al (2005) Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. Mol Ther 12(6):1072–1082
Bainbridge JW et al (2008) Effect of gene therapy on visual function in Leber’s congenital amaurosis. N Engl J Med 358(21):2231–2239
Dudus L et al (1999) Persistent transgene product in retina, optic nerve and brain after intraocular injection of rAAV. Vision Res 39(15):2545–2553
Chadderton N et al (2013) Intravitreal delivery of AAV-NDI1 provides functional benefit in a murine model of Leber hereditary optic neuropathy. Eur J Hum Genet 21(1):62–68
Drolet DW et al (2000) Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of rhesus monkeys. Pharm Res 17(12):1503–1510
Hangai M et al (1998) In vivo delivery of phosphorothioate oligonucleotides into murine retina. Arch Ophthalmol 116(3):342–348
Thrimawithana TR et al (2011) Drug delivery to the posterior segment of the eye. Drug Discov Today 16(5–6):270–277
Saishin Y et al (2005) Periocular gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization in a human-sized eye. Hum Gene Ther 16(4):473–478
Martin KR, Klein RL, Quigley HA (2002) Gene delivery to the eye using adeno-associated viral vectors. Methods 28(2):267–275
Rabinowitz JE et al (2002) Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol 76(2):791–801
Flannery JG et al (1997) Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus. Proc Natl Acad Sci U S A 94(13):6916–6921
Zhou S et al (2010) Ultrasound-targeted microbubble destruction mediated herpes simplex virus-thymidine kinase gene treats hepatoma in mice. J Exp Clin Cancer Res 29:170
Hu YZ et al (2009) Ultrasound microbubble contrast agents: application to therapy for peripheral vascular disease. Adv Ther 26(4):425–434
Wood SC et al (2012) Effects of ultrasound and ultrasound contrast agent on vascular tissue. Cardiovasc Ultrasound 10(1):29
Unger EC et al (2001) Local drug and gene delivery through microbubbles. Prog Cardiovasc Dis 44(1):45–54
Lai CC et al (2001) Suppression of choroidal neovascularization by adeno-associated virus vector expressing angiostatin. Invest Ophthalmol Vis Sci 42(10):2401–2407
Takahashi T et al (2000) Inhibition of experimental choroidal neovascularization by overexpression of tissue inhibitor of metalloproteinases-3 in retinal pigment epithelium cells. Am J Ophthalmol 130(6):774–781
Zhou XY et al (2009) Ultrasound-mediated microbubble delivery of pigment epithelium-derived factor gene into retina inhibits choroidal neovascularization. Chin Med J (Engl) 122(22):2711–2717
Garcia-Frigola C et al (2007) Gene delivery into mouse retinal ganglion cells by in utero electroporation. BMC Dev Biol 7:103
Dezawa M et al (2002) Gene transfer into retinal ganglion cells by in vivo electroporation: a new approach. Micron 33(1):1–6
Souied EH et al (2008) Non-invasive gene transfer by iontophoresis for therapy of an inherited retinal degeneration. Exp Eye Res 87(3):168–175
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Controlled Release Society
About this chapter
Cite this chapter
Shukla, R.S., Cheng, K. (2014). Site-Specific Ocular Nucleic Acid Delivery. In: Domb, A., Khan, W. (eds) Focal Controlled Drug Delivery. Advances in Delivery Science and Technology. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-9434-8_11
Download citation
DOI: https://doi.org/10.1007/978-1-4614-9434-8_11
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4614-9433-1
Online ISBN: 978-1-4614-9434-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)